Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 18/20 | 0.57 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495855 | 0.88 | BRD4 (0.45) | SYKZAP70JAK2JAK3 | |
| SCHEMBL3494922 | 0.86 | SYK (0.51) | SYKJAK3 | |
| SCHEMBL3496522 | 0.85 | SYK (0.64) | SYK | |
| SCHEMBL3495869 | 0.83 | SYK (0.46) | SYKJAK3 | |
| SCHEMBL3496111 | 0.79 | SYK (0.58) | SYKZAP70JAK3 | |
| SCHEMBL3495615 | 0.79 | SYK (0.55) | SYK | |
| SCHEMBL3496405 | 0.79 | SYK (0.51) | SYK | |
| SCHEMBL3494833 | 0.78 | EPHB4 (0.47) | SYK | |
| SCHEMBL3494982 | 0.78 | SYK (0.56) | SYKJAK2 | |
| SCHEMBL3495176 | 0.77 | SYK (0.70) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | SYK 460/4885ZAP70 186/4885JAK2 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.